So boys & girls go back and look at P2 results .... increase in survival was 6.9 Months
Yes the shorts point to PSA rates So What. .... thats not the primary end point.
The Drug has both an SPA and Fast track FDA Designation. Both very important to a speedy Filing
so as long as the P3 trial meets SPA trial end point its a done deal.